Zacks CommentaryNOV 42 min read$NAGE

Niagen Bioscience (NAGE) Surpasses Q3 Earnings and Revenue Estimates

Niagen Bioscience (NAGE) delivered earnings and revenue surprises of +150.00% and +8.58%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Original reporting

Zacks Commentary · Zacks Equity Research

Published Nov 4, 2025, 11:00 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 5, 2025, 1:31 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Niagen Bioscience (NAGE) Surpasses Q3 Earnings and Revenue Estimates — source image — Source · www.zacks.com

Decision brief

The 30-second read

$NAGEBullishHigh

Why it matters

The strong quarterly results could lead to short-term price appreciation, attracting momentum traders.

Market read

The news is highly relevant for investors interested in biotech and health sectors, with potential for short-term trading opportunities.

What to watch

Potential overvaluation if stock price has already priced in the earnings surprise; macroeconomic factors could impact sector performance.

Relevance 6/10Timing: Immediate, as the earnings report is recent and market reacts quickly

Background

Niagen Bioscience specializes in health supplements, with recent earnings surpassing expectations, indicating operational strength.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$NAGEBullishHigh confidence

Context

Primary focus of the news, significant earnings beat

Expected impact

Moderate upward movement in the short term, potential for sustained growth if fundamentals remain strong.

Evidence & confidence

The substantial earnings beat and revenue growth are strong indicators of company strength, likely to attract investor interest and support stock price.

Market effects

Sector

Positive impact on biotech and health supplement sectors, as Niagen Bioscience operates within these areas

Regional

Limited regional impact, primarily affecting investor sentiment in the company's primary market

Global

Moderate, as the company may be part of global health and biotech trends

Counterpoint

What could challenge this read

The earnings beat may be a one-time event; future performance depends on sustained growth and market conditions.

Key entities

Company
Niagen Bioscience
A biotech company focusing on health supplements.

Read at source ← All news

OCT 22

$NAGEMedAI 8/10

Two pilot studies associated Niagen injections with less fatigue and better sleep

Niagen Bioscience (NASDAQ: NAGE) published two pilot studies showing injectable Niagen was well-tolerated and associated with reduced fatigue, improved sleep, and skin health. The studies involved 39 adults with elevated fatigue. The company launched a liquid Niagen At-Home Injection Kit, aiming to scale its telehealth platform. Results are exploratory and require larger, placebo-controlled studies.

stocktitan.net2 min

OCT 5

$NAGEHighAI 8/10

Canaccord reiterates Niagen stock rating on healthy aging strategy

Canaccord Genuity reiterated a Buy rating and $10.00 price target on Niagen Bioscience (NAGE) after meeting with management. The company aims to expand beyond supplements into healthy aging, therapeutics, and skincare. Despite slower growth in 2026, Canaccord expects a return to double-digit growth in late 2026 and 2027. NAGE trades at 1.2x EV/Sales and 11.7x EV/EBITDA, below peer M&A averages.

investing.com2 min

AUG 4

$NAGEMed

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

Niagen Bioscience, Inc. (NAGE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results Launched pharmaceutical program targeting rare genetic diseases and aging related disorders in July Launched Niagen Plus telehealth platform Net sales of $29.8 million, including $24.2 million from Tru Niagen G

SEC EDGAR 8-K6 min

JUL 13

$NAGEMedAI 8/10

Niagen Gains on FDA Nod

Niagen Bioscience (NASDAQ: NAGE) said the FDA granted Rare Pediatric Disease designation to its lead small-molecule candidate NB4168 for Ataxia Telangiectasia (A-T). The company also reported the EMA granted Orphan Medicinal Product designation for NB4168 in the EU. The designations recognize A-T as serious and life-threatening and provide development incentives.

baystreet.ca2 min

JUL 8

$NAGEMed

2026-07-08 | Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases | NDAQ:NAGE | Press Release

Niagen Bioscience (NASDAQ: NAGE) said it launched a regulated drug development program via its wholly owned subsidiary NAD Pharmaceuticals. The first candidate, NB4168, is a proprietary oral derivative of NR aimed at higher bioavailability. Initial indication is Ataxia Telangiectasia, a rare ATM-gene disease with no FDA-approved therapies, and nonclinical PK data show higher blood exposure than NR chloride.

stockhouse.com4 min

OCT 31

$YPFMedAI 8/10

YPF Seeks Incentives for US$8.7B Shale Plan

YPF, Argentina's state-owned oil company, applied for US$8.7B shale oil project in Vaca Muerta under Argentina's RIGI incentive regime. The project, Bajo del Toro, expects US$25B exports between 2027-2055. YPF plans two more projects, totaling US$44B investment. YPF reported Q3 profit of US$1.2B and Q3 EBITDA of US$2.5B.

riotimesonline.com2 min